News from blueprint medicines A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 14, 2019, 08:00 ET Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Nov 06, 2019, 09:00 ET Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Nov 05, 2019, 07:00 ET Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Oct 29, 2019, 08:00 ET Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019

Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Aug 28, 2019, 08:00 ET Blueprint Medicines to Present at Upcoming Investor Conferences in September

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Aug 07, 2019, 08:00 ET Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Aug 06, 2019, 08:00 ET Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Aug 01, 2019, 07:00 ET Blueprint Medicines Reports Second Quarter 2019 Financial Results

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Jul 25, 2019, 08:00 ET Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Jun 15, 2019, 06:00 ET Blueprint Medicines Presents Updated EXPLORER Trial Data for Avapritinib in Patients with Systemic Mastocytosis at 24th EHA Congress

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Jun 14, 2019, 08:45 ET Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Jun 03, 2019, 09:00 ET Blueprint Medicines' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019

-- 60% ORR in post-platinum RET-fusion NSCLC and 63% ORR in RET-mutant MTC patients previously treated with multi-kinase inhibitors; median durations ...

May 09, 2019, 07:00 ET Blueprint Medicines Reports First Quarter 2019 Financial Results

Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

May 08, 2019, 08:00 ET Blueprint Medicines to Present at Bank of America Merrill Lynch 2019 Health Care Conference

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

May 02, 2019, 08:00 ET Blueprint Medicines to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Apr 02, 2019, 16:01 ET Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Mar 28, 2019, 20:40 ET Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Mar 27, 2019, 16:03 ET Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Mar 27, 2019, 16:00 ET Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Mar 05, 2019, 08:01 ET Blueprint Medicines to Present at 39th Annual Cowen & Co. Health Care Conference

Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Feb 19, 2019, 08:00 ET Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Feb 07, 2019, 16:01 ET Blueprint Medicines to Present at Upcoming Investor Conferences in February

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Jan 04, 2019, 08:00 ET Blueprint Medicines Announces "2020 Blueprint" Global Business Strategy and Outlines Key Corporate Goals

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer...

Dec 02, 2018, 12:30 ET Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically...

Nov 15, 2018, 07:00 ET Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically...